This article aims to provide an overview of the role of combined radiation and androgen deprivation (ADT) therapy in patients with intermediate-risk prostate cancer.
The current German, European, and NCCN (National Comprehensive Cancer Network) guidelines as well as relevant literature in the PubMed database which provide information on sub-classification within the intermediate-risk group and the use of ADT in terms of oncological outcome were reviewed.
Read the article on URO Today HERE
Prostate Cancer Foundation’s goal is always to deliver the most cutting-edge treatments and information to families dealing with prostate cancer. As such, they have committed to updating the patient guide to reflect the very latest research and discoveries for patients.
This is our third round of updates for 2019. Changes include:
- Updated information on local treatments for recurrent prostate cancer
- Updated information on therapies for metastatic hormone-sensitive prostate cancer
- New FDA approval of darolutamide for non-metastatic CRPC
- New information about non-hormonal therapy options for select patients
- New information on the use of PARP inhibitors as an emerging therapy
- Updated recommendations on when to talk to your doctor about PSA screening
- Updated nutrition recommendations
Download an updated digital copy today and then be sure to provide feedback.
U.S. Food and Drug Administration (FDA) approved a new use for enzalutamide (Xtandi®) for the treatment of metastatic hormone-sensitive (aka, “castration-sensitive”) prostate cancer (mHSPC). Enzalutamide has previously been FDA-approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC).
Read the summary on PCF.org HERE
Read the approval on FDA.gov HERE
URO Today has published a collection of videos from the APCC 2019 conference. This informative collection of 60 short videos cover a wide range of prostate cancer topics. You can view the video collection on URO Today HERE
Food and Drug Administration (FDA) approved apalutamide (Erleada) for the treatment of metastatic hormone-sensitive (aka, “castration-sensitive”) prostate cancer (mHSPC). Apalutamide has previously received FDA-approval for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC).
Read the entire article on pcf.org HERE
Opinion Article by Charles Maack
The information in this article is a lengthy read, but for men moved to androgen deprivation therapy the information is extremely important to be aware since everything explained may be involved in their well-being.
Triple-hormonal blockade/androgen deprivation therapy (ADT3) includes the prescribing of:
- a LHRH/GnRH agonist or antagonist to shut down testicular testosterone production
- an antiandrogen to block testosterone access to the cancer cell nucleus
- a 5Alpha Reductase (5AR) inhibitor to prevent any testosterone that might access the cancer cell nucleus from converting to dihydrotestosterone/DHT
Read the entire article on oncogen.org HERE
Scientists at Cedars-Sinai have discovered how prostate cancer can sometimes withstand and outwit a standard hormone therapy, causing the cancer to spread. Their findings also point to a simple blood test that may help doctors predict when this type of hormone therapy resistance will occur. Learn more about these interesting findings by clicking HERE.
Once a man is castrate resistant and moves on a second line hormone therapy drug like Zytiga or Xtandi (aka AR inhibitors) it is inevitable that the Zytiga or Xtandi will also become ineffective.
When this happens, the question that comes is what should be the next treatment? Generally, the options currently available are either to move to the drug not initially used ( Zytiga if Xtandi was first used or Xtandi if Zytiga was used) or instead to use taxane chemotherapy (Taxotere aka docetaxel).
Knowing which of these two options is best has been nothing but guesswork. But, things are improving. There is an investigational test that detects the expression of a protein called AR-V7 in the nuclei of circulating tumor cells taken from a vial of blood cells (liquid biopsy). This test can help guide this decision.
A recent study (published in JAMA Oncology) evaluating this test has shown that a blood test can detect the protein called AR-V7 in circulating tumor cells and that the presence of this protein accurately predicts how well certain men will respond to AR inhibitors (Zytiga and Xtandi).
Read the complete blog on CancerABCs.org HERE
The U.S. Food and Drug Administration (FDA) approved a new use for enzalutamide (Xtandi) for the treatment of non-metastatic castration-resistant prostate cancer (non-metastatic CRPC). Enzalutamide was previously approved only for patients with metastatic CRPC. Prior to this past February – when the FDA also approved apalutamide (Erleada) for non-metastatic CRPC – there were no FDA-approved treatments for these men.
Read more on PCF.org HERE
It has just been recently announced that the U.S. Food and Drug Administration (FDA) has approved a generic version of Zytiga, the new drug’s name is Yonsa. It is a novel formulation of abiraterone acetate that needs to be used in combination with methylprednisolone for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC).
Read the complete article on CancerABCs.org HERE